T. Sakurama

Tissue-type plasminogen activator improves neurological functions in a rat model of thromboembolic stroke.

T. Sakurama, R. Kitamura, M. Kaneko, 1994, Stroke.

Comparative studies of thrombolysis with single-chain and two-chain recombinant tissue-type plasminogen activators in canine coronary thrombosis.

K. Matsui, O. Matsuo, S. Ueshima, 1996, Journal of cardiovascular pharmacology.

Protective effects of SM-20302, an orally active GPIIb/IIIa antagonist, in an ADP/epinephrine-induced guinea pig model of transient cerebral ischemia.

T. Sakurama, M. Kaneko, S. Horisawa, 2001, Thrombosis research.

Antithrombotic effect of SM-20302, a nonpeptide GPIIb/IIIa antagonist, in a photochemically induced thrombosis model in guinea pigs.

Y. Ikeda, T. Sakurama, M. Kaneko, 1999, Thrombosis research.

Temporary and partial inhibition of platelets by SM-20302 prevents coronary artery thrombosis in a chronic canine model.

B. Lucchesi, S. Rebello, T. Sakurama, 1999, European journal of pharmacology.

SM-20302, a Nonpeptide GPIIb/IIIa Receptor Antagonist, Exhibits a Wide Therapeutic Window in a Newly Developed Hemorrhage Model in Mice*

T. Sakurama, M. Kaneko, S. Horisawa, 1999, Thrombosis and Haemostasis.

Intermittent cyclical etidronate treatment maintains the mass, structure and the mechanical property of bone in ovariectomized rats

Toshitaka Nakamura, H. Ohnishi, T. Katsumata, 1995, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

The problem of the assay for tissue plasminogen activator, obtained from various sources, with the fibrin plate method

A. Takada, T. Sakurama, M. Kaneko, 1989 .